A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Inclusion Criteria:

- Be 18 years old at the time the informed consent is signed

- Have a histologically or cytologically confirmed adenocarcinoma or poorly
differentiated carcinoma of the prostate

- Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL
(1.73 nM)

- Be eligible for treatment with physician's choice of comparator treatment (abiraterone
acetate, enzalutamide or docetaxel)

- Experienced disease progression after having received 1 prior next generation androgen
receptor-targeted therapy for castration-resistant disease

- Have a deleterious mutation in a BRCA1/2 or ATM gene

Exclusion Criteria:

- Active second malignancy, with the exception of curatively treated non melanoma skin
cancer, carcinoma in situ, or superficial bladder cancer

- Prior treatment with any PARP inhibitor

- Prior treatment with chemotherapy for metastatic castration-resistant prostate cancer

- Symptomatic and/or untreated central nervous system metastases

- Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would,
in the opinion of the investigator, interfere with absorption of study drug